Allergan expands Restasis sales force to fight off Shire's new dry eye threat

Allergan has insisted that it’s not afraid of Xiidra, Shire’s brand-new dry eye contender. But it’s adding to its sales force to ensure it has nothing to worry about.

The Dublin drugmaker has added 60 reps to its ranks to protect blockbuster Restasis, bulking up its sales corps by 20%, Allergan commercial chief Bill Meury said on Monday’s Q2 conference call. And the new faces join a “very highly trained, experienced sales force with great relationships in both areas of eye care,” he reminded investors.

That’s not the only move Allergan is making to keep up with the new competition. It has also upped its spending on DTC advertising for Restasis, and it expanded the sampling programs on that med and on its artificial tears product, Meury said.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Insurance coverage will be broader in the second half of the year than it was in the first, and “we’ve shored up formulary coverage at virtually every health plan across the country both on the commercial and the [Medicare] Part D side,” Meury said.

The way analysts see it, Allergan has good reason to shore up its defenses. Shire's Xiidra--the first product to win approval specifically for dry eye, rather than tear production--boasts a label that’s “clearly better,” Evercore ISI analyst Umer Raffat wrote to clients after that drug's FDA win. And Xiidra is rolling out at the same price as Allergan’s product.

Even so, industry watchers aren’t predicting a doomsday scenario for Allergan. As Raffat says, even if Xiidra does nab somewhere in the neighborhood of 30% of Restasis volume over time, Allergan may be able to offset about 10% to 15% of that through price increases. And Bernstein analyst Ronny Gal has said that Allergan’s “power of incumbency” will likely help shape a “stable oligopoly” between the two products.

- read the call transcript

Related Articles:
Shire targets Allergan's dry-eye market share by pricing Xiidra at $5K per year--right on par with Restasis
Shire's new dry-eye approval means it's time for an Allergan showdown
Allergan's Restasis defense stumbles at FDA as Shire loads up lifitegrast assault 
Allergan pooh-poohs threat from Shire's prospective dry-eye drug 
Shire's back on track with its dry-eye threat to Allergan's Restasis 
Shire's eye drug setback gives Allergan's Restasis a temporary reprieve


Suggested Articles

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

Rather than "we did the best we could," Vas Narasimhan, during an internal call with managers, said Novartis could have handled the Zolgensma crisis…

After five years of struggles, Sun Pharmaceutical has put the problems at its key plant in Halol, India behind it.